Preoperative CT-based Radiomic Prognostic Index to Predict the Benefit of Postoperative Radiotherapy in Patients with Non-small Cell Lung Cancer: a Multicenter Study

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2024 May 14

PMID 38741207

Authors

Zeliang Ma

Yu Men

Yunsong Liu

Yongxing Bao

Qian Liu

Xu Yang

Jianyang Wang

Lei Deng

Yirui Zhai

Nan Bi

Luhua Wang

Zhouguang Hui

Affiliations

Soon will be listed here.

Abstract

Background: The value of postoperative radiotherapy (PORT) for patients with non-small cell lung cancer (NSCLC) remains controversial. A subset of patients may benefit from PORT. We aimed to identify patients with NSCLC who could benefit from PORT.

Methods: Patients from cohorts 1 and 2 with pathological Tany N2 M0 NSCLC were included, as well as patients with non-metastatic NSCLC from cohorts 3 to 6. The radiomic prognostic index (RPI) was developed using radiomic texture features extracted from the primary lung nodule in preoperative chest CT scans in cohort 1 and validated in other cohorts. We employed a least absolute shrinkage and selection operator-Cox regularisation model for data dimension reduction, feature selection, and the construction of the RPI. We created a lymph-radiomic prognostic index (LRPI) by combining RPI and positive lymph node number (PLN). We compared the outcomes of patients who received PORT against those who did not in the subgroups determined by the LRPI.

Results: In total, 228, 1003, 144, 422, 19, and 21 patients were eligible in cohorts 1-6. RPI predicted overall survival (OS) in all six cohorts: cohort 1 (HR = 2.31, 95% CI: 1.18-4.52), cohort 2 (HR = 1.64, 95% CI: 1.26-2.14), cohort 3 (HR = 2.53, 95% CI: 1.45-4.3), cohort 4 (HR = 1.24, 95% CI: 1.01-1.52), cohort 5 (HR = 2.56, 95% CI: 0.73-9.02), cohort 6 (HR = 2.30, 95% CI: 0.53-10.03). LRPI predicted OS (C-index: 0.68, 95% CI: 0.60-0.75) better than the pT stage (C-index: 0.57, 95% CI: 0.50-0.63), pT + PLN (C-index: 0.58, 95% CI: 0.46-0.70), and RPI (C-index: 0.65, 95% CI: 0.54-0.75). The LRPI was used to categorize individuals into three risk groups; patients in the moderate-risk group benefited from PORT (HR = 0.60, 95% CI: 0.40-0.91; p = 0.02), while patients in the low-risk and high-risk groups did not.

Conclusions: We developed preoperative CT-based radiomic and lymph-radiomic prognostic indexes capable of predicting OS and the benefits of PORT for patients with NSCLC.

Citing Articles

Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.

Ma Z, Liu Y, Bao Y, Liu Q, Yang X, Men Y BMC Cancer. 2024; 24(1):968.

PMID: 39112971 PMC: 11308139. DOI: 10.1186/s12885-024-12699-4.

Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis.

Feier C, Muntean C, Faur A, Gaborean V, Petrache I, Cozma G J Pers Med. 2024; 14(6).

PMID: 38929773 PMC: 11204880. DOI: 10.3390/jpm14060552.

References

Suveg K, Le Pechoux C, Faivre-Finn C, Putora P, De Ruysscher D, Widder J . Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART. Clin Lung Cancer. 2021; 22(6):579-586. DOI: 10.1016/j.cllc.2021.08.007. View

Ma Z, Liang B, Wei R, Liu Y, Bao Y, Yuan M . Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: Dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial. Thorac Cancer. 2023; 14(28):2839-2845. PMC: 10542460. DOI: 10.1111/1759-7714.15068. View

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B . Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 23(1):104-114. DOI: 10.1016/S1470-2045(21)00606-9. View

Wang T, She Y, Yang Y, Liu X, Chen S, Zhong Y . Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer. Radiology. 2021; 302(2):425-434. DOI: 10.1148/radiol.2021210109. View

Zarinshenas R, Ladbury C, McGee H, Raz D, Erhunmwunsee L, Pathak R . Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022; 173:10-18. DOI: 10.1016/j.radonc.2022.05.019. View

Yuan M, Zhai Y, Men Y, Zhao M, Sun X, Ma Z . Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer. Thorac Cancer. 2022; 13(23):3331-3340. PMC: 9715775. DOI: 10.1111/1759-7714.14689. View

Choi Y, Aum J, Lee S, Kim H, Kim J, Shin S . Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma. Cancers (Basel). 2021; 13(16). PMC: 8391458. DOI: 10.3390/cancers13164077. View

Dai H, Hui Z, Ji W, Liang J, Lu J, Ou G . Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist. 2011; 16(5):641-50. PMC: 3228200. DOI: 10.1634/theoncologist.2010-0343. View

10.

Bao Y, Yang X, Men Y, Kang J, Sun X, Zhao M . Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database. Thorac Cancer. 2021; 13(3):404-411. PMC: 8807257. DOI: 10.1111/1759-7714.14273. View

11.

Sun X, Men Y, Wang J, Bao Y, Yang X, Zhao M . Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Thorac Cancer. 2021; 12(9):1358-1365. PMC: 8088942. DOI: 10.1111/1759-7714.13908. View

12.

Lockney N, Yang T, Barron D, Gelb E, Gelblum D, Yorke E . PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 2018; 7:91-93. PMC: 5830173. DOI: 10.1016/j.ctro.2017.11.002. View

13.

Liu Y, Wang Y, Wang X, Xue L, Zhang H, Ma Z . MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study. Cancer Imaging. 2024; 24(1):16. PMC: 10804642. DOI: 10.1186/s40644-024-00659-x. View

14.

Zhang N, Liang R, Gensheimer M, Guo M, Zhu H, Yu J . Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. Theranostics. 2020; 10(25):11707-11718. PMC: 7546006. DOI: 10.7150/thno.50565. View

15.

Yu L, Tao G, Zhu L, Wang G, Li Z, Ye J . Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis. BMC Cancer. 2019; 19(1):464. PMC: 6525347. DOI: 10.1186/s12885-019-5646-9. View

16.

Huang S, Yang J, Shen N, Xu Q, Zhao Q . Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective. Semin Cancer Biol. 2023; 89:30-37. DOI: 10.1016/j.semcancer.2023.01.006. View

17.

Ding X, Hui Z, Dai H, Fan C, Men Y, Ji W . A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(9):1565-73. DOI: 10.1016/j.jtho.2016.05.004. View

18.

Yuan M, Zhai Y, Men Y, Wang J, Deng L, Wang W . Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer. 2021; 12(23):3208-3215. PMC: 8636201. DOI: 10.1111/1759-7714.14188. View

19.

Chiappetta M, Leuzzi G, Sperduti I, Bria E, Mucilli F, Lococo F . Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis. Clin Lung Cancer. 2020; 21(5):464-471.e1. DOI: 10.1016/j.cllc.2020.03.004. View

20.

Yuan M, Men Y, Kang J, Sun X, Zhao M, Bao Y . Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins. Thorac Cancer. 2020; 12(2):227-234. PMC: 7812075. DOI: 10.1111/1759-7714.13749. View